Today the National Institute for Health and Care Excellence (NICE) recommended enzalutamide, within its marketing authorisation, for the treatment of metastatic hormone-relapsed prostate cancer that has progressed during or after docetaxel-containing chemotherapy, but only if the manufacturer provides enzalutamide with the discount agreed in the patient access scheme. NICE appraised enzalutamide under the Single Technology Appraisal process. The key evidence came from the AFFIRM trial. Enzalutamide extended median survival by 4·5 months compared with placebo (17·8 months vs 13·3 months; hazard ratio [HR] 0·62 [95% CI 0·52—0·73]; p
Posted on: Wed, 23 Jul 2014 14:00:26 +0000
Recently Viewed Topics
© 2015